Sheena Jonathan sold $1.3M of NTRA

Sheena Jonathan sold 3,150 shares of Natera, Inc. (NTRA) at an average of $410.55 ($406.50–$416.67, $1.29M total) across 8 trades on 2026-10-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Oct 24, 2026, 1:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale may prompt short‑term price scrutiny but is unlikely to drive a sustained move.

02

Market read

A modest insider sale by a director, reported via Form 4, offers limited trading relevance.

03

What to watch

The director's holdings remain sizable, and the sale was pre‑arranged under a 10b5‑1 plan, reducing interpretive weight.

Relevance 5/10Novelty 4/10Timing: post‑market filing

Background

SEC Form 4 filings disclose insider transactions; a director's sale is publicly reported and often monitored by traders.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Director Sheena Jonathan sold 3,150 shares of Natera for $1.3M via a 10b5‑1 plan, reducing her stake to 218,164 shares.

Expected impact

likely slight downward pressure as the market prices the director's sale

Evidence & confidence

A $1.3M sale by a director is material enough to attract attention, but the amount is modest relative to market cap, so impact is limited.

Market effects

Minimal; the sale does not affect the broader biotech sector.

None; the filing is company‑specific.

Low; only relevant to investors tracking Natera.

Counterpoint

The sale could be routine liquidity management and not a negative signal.

Key entities

  • Sheena Jonathan

    Director of Natera who executed the sale.

  • Natera, Inc.

    US‑listed biotech company (ticker NTRA).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.